Woodline Partners’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $9.19M | Buy |
530,923
+312,073
| +143% | +$5.4M | 0.05% | 447 |
|
|
2025
Q1 | $4.79M | Buy |
218,850
+29,373
| +16% | +$642K | 0.03% | 520 |
|
|
2024
Q4 | $6.05M | Buy |
189,477
+913
| +0.5% | +$29.1K | 0.04% | 445 |
|
|
2024
Q3 | $5.44M | Buy |
188,564
+1,564
| +0.8% | +$45.1K | 0.05% | 377 |
|
|
2024
Q2 | $7.17M | Buy |
187,000
+2
| +0% | +$77 | 0.07% | 290 |
|
|
2024
Q1 | $11M | Buy |
186,998
+774
| +0.4% | +$45.5K | 0.1% | 248 |
|
|
2023
Q4 | $11.1M | Buy |
+186,224
| New | +$11.1M | 0.12% | 217 |
|
|
2023
Q1 | – | Sell |
-70,651
| Closed | -$3.65M | – | 632 |
|
|
2022
Q4 | $3.65M | Buy |
+70,651
| New | +$3.65M | 0.05% | 367 |
|
|
2022
Q1 | – | Sell |
-41,199
| Closed | -$1.95M | – | 720 |
|
|
2021
Q4 | $1.95M | Sell |
41,199
-66,877
| -62% | -$3.16M | 0.03% | 424 |
|
|
2021
Q3 | $3.56M | Buy |
+108,076
| New | +$3.56M | 0.06% | 304 |
|
|
2021
Q2 | – | Sell |
-171,419
| Closed | -$7.36M | – | 592 |
|
|
2021
Q1 | $7.36M | Buy |
+171,419
| New | +$7.36M | 0.16% | 159 |
|
|
2020
Q2 | – | Sell |
-224,948
| Closed | -$6.03M | – | 153 |
|
|
2020
Q1 | $6.03M | Buy |
224,948
+92,001
| +69% | +$2.46M | 0.43% | 73 |
|
|
2019
Q4 | $4.07M | Buy |
+132,947
| New | +$4.07M | 0.17% | 95 |
|